Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lipson

Showing results (141-150 of 205) with videos related to

Pageof 21
Sort By:
Cell Reports. Medicine|February 22, 2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinomaJulie Stein Deutsch, Evan J Lipson, Ludmila Danilova, et al.
JAMA Oncology|March 24, 2017
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for ImmunotherapyElizabeth L Yanik, Genevieve J Kaunitz, Tricia R Cottrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint InhibitorsFyza Y Shaikh, James R White, Joell J Gills, et al.
Elife|June 28, 2013
Evolutionary dynamics of cancer in response to targeted combination therapyIvana Bozic, Johannes G Reiter, Benjamin Allen, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockadeJulie Stein Deutsch, Jonathan Lai, Kara M Schenk, et al.
Journal of Translational Medicine|July 6, 2015
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant settingEvan J Lipson, William H Sharfman, Shuming Chen, et al.
Journal for Immunotherapy of Cancer|September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
The Oncologist|April 19, 2019
Sicca Syndrome Associated with Immune Checkpoint Inhibitor TherapyBlake M Warner, Alan N Baer, Evan J Lipson, et al.
Nature Immunology|July 15, 2020
Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunityChang Liu, Ashwin Somasundaram, Sasikanth Manne, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Pageof 21

Showing results (141-150 of 205) with videos related to

Sort By:
Pageof 21
Cell Reports. Medicine|February 22, 2023
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinomaJulie Stein Deutsch, Evan J Lipson, Ludmila Danilova, et al.
JAMA Oncology|March 24, 2017
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for ImmunotherapyElizabeth L Yanik, Genevieve J Kaunitz, Tricia R Cottrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2021
A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint InhibitorsFyza Y Shaikh, James R White, Joell J Gills, et al.
Elife|June 28, 2013
Evolutionary dynamics of cancer in response to targeted combination therapyIvana Bozic, Johannes G Reiter, Benjamin Allen, et al.
Journal for Immunotherapy of Cancer|December 15, 2023
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockadeJulie Stein Deutsch, Jonathan Lai, Kara M Schenk, et al.
Journal of Translational Medicine|July 6, 2015
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant settingEvan J Lipson, William H Sharfman, Shuming Chen, et al.
Journal for Immunotherapy of Cancer|September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
The Oncologist|April 19, 2019
Sicca Syndrome Associated with Immune Checkpoint Inhibitor TherapyBlake M Warner, Alan N Baer, Evan J Lipson, et al.
Nature Immunology|July 15, 2020
Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunityChang Liu, Ashwin Somasundaram, Sasikanth Manne, et al.
Journal for Immunotherapy of Cancer|June 25, 2025
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapyRyan J Sullivan, Anthony R Cillo, Robert L Ferris, et al.
Pageof 21